Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020

Area of Science:

• Public Health
• Infectious Diseases
• Microbiology

Background:

• Sexually transmitted infections (STIs) caused by Neisseria gonorrhoeae have significantly increased, leading to severe health complications like infertility and facilitating HIV transmission.
• Antimicrobial resistance in N. gonorrhoeae complicates treatment and control efforts, necessitating updated therapeutic strategies.
• Previous guidelines recommended dual therapy (ceftriaxone and azithromycin) to prevent resistance and treat coinfections, but this is being reevaluated.

Purpose of the Study:

• To update treatment guidelines for uncomplicated gonorrhea based on evolving antimicrobial resistance patterns.
• To address concerns regarding antimicrobial stewardship and the impact of dual therapy on commensal organisms.

Main Methods:

• This report updates previous guidelines (5) based on current surveillance data and resistance trends.
• The study involved a reevaluation of the recommended treatment regimen for gonococcal infections.

Main Results:

• The updated recommendation is a single 500 mg intramuscular (IM) dose of ceftriaxone for uncomplicated urogenital, anorectal, and pharyngeal gonorrhea.
• Concurrent treatment with doxycycline (100 mg orally twice daily for 7 days) is advised if chlamydial infection is not excluded.

Conclusions:

• The updated guidelines aim to optimize gonorrhea treatment efficacy while promoting antimicrobial stewardship.
• Continuous monitoring for ceftriaxone resistance and reporting of treatment failures are crucial for maintaining effective gonorrhea control strategies.